ASCO Education Podcast
Summary: The ASCO Education Podcast is an educational series focused on helping learners identify knowledge gaps and stay up-to-date with the latest in new drug developments, cancer treatments and patient care approaches. The purpose of this podcast is to educate and to inform. This podcast is provided on the understanding that it does not constitute medical or other professional advice or services. It is no substitute for professional care by a doctor or other qualified medical professional and is not intended for use in the diagnosis or treatment of individual conditions. Guests who speak in this podcast express their own opinions, experience and conclusions. Neither American Society of Clinical Oncology nor any of its affiliates endorses, supports or opposes any particular treatment option or other matter discussed in this podcast. The mention of any product, service, organization, activity or therapy on the Podcast should not be construed as an ASCO endorsement.
- Visit Website
- RSS
- Artist: ASCO eLearning
- Copyright:
Podcasts:
Annual Meeting 2018 - ASCO Voices: Did You Ever Know That You're My Hero
Self-Evaluation: Gastric Cancer Diagnosis
ASCO Guideline: Practical Assessment and Management of Vulnerabilities
Self-Evaluation: Small Cell Lung Cancer
Recently Approved Drugs: Nivolumab for patients with metastatic small cell lung cancer
ASCO Guideline: Palliative Care in the Global Setting
692474
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a variety of immunotherapy treatments and how they increase an immune response against tumors.
Rachel Freedman, MD, MPH- Assistant Professor, Medicine, Harvard Medical School, Dana-Farber Cancer Institute presents a self-assessment question from an ASCO University course focusing on the treatment breast cancer.
Special Episode: Non-Hodgkin Lymphoma
Annual Meeting 2018 - ASCO Voices: The Call
Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
ASCO Guideline: Antiemetics Guideline for Treatment-Induced Nausea and Vomiting
Self-Evaluation: Breast
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
